How Analysts Feel About Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?

February 15, 2018 - By Michael Collier

 How Analysts Feel About Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?
Investors sentiment increased to 2.8 in Q3 2017. Its up 2.26, from 0.54 in 2017Q2. It is positive, as 8 investors sold Marinus Pharmaceuticals, Inc. shares while 2 reduced holdings. 20 funds opened positions while 8 raised stakes. 18.97 million shares or 171.42% more from 6.99 million shares in 2017Q2 were reported.
Orbimed Lc invested in 0.03% or 567,600 shares. Jennison Assocs Lc holds 1.61M shares. Shanda Asset Ltd holds 0.01% or 10,000 shares. Citadel Advisors Limited Liability Co owns 0% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 51,383 shares. Ellington Mngmt Lc, Connecticut-based fund reported 45,100 shares. 867,927 are owned by Millennium Mngmt Limited Liability Corp. Franklin Res stated it has 2.18 million shares or 0.01% of all its holdings. National Bank Of Ny Mellon Corporation reported 21,842 shares. Deutsche Bank Ag owns 0% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 200 shares. Farallon Capital Management Limited Liability Company reported 1.17 million shares. Caxton Corp holds 16,198 shares or 0.1% of its portfolio. Deerfield invested 0.36% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Northern Trust Corp reported 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Virtu Fincl Limited Liability reported 11,296 shares stake. Moreover, Bogle Inv Mgmt L P De has 0.15% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 382,619 shares.

Since December 15, 2017, it had 0 insider purchases, and 2 insider sales for $10.05 million activity. Bain Capital Life Sciences Investors – LLC sold 1.27M shares worth $10.02 million.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Ratings Coverage

Among 4 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Marinus Pharmaceuticals had 9 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Oppenheimer on Wednesday, August 5. Oppenheimer downgraded the stock to “Perform” rating in Tuesday, June 14 report. The stock has “Sector Perform” rating by RBC Capital Markets on Tuesday, June 14. RBC Capital Markets initiated it with “Outperform” rating and $14 target in Thursday, December 17 report. The firm has “Outperform” rating given on Friday, October 30 by Oppenheimer. The company was initiated on Tuesday, November 17 by Jefferies. Stifel Nicolaus maintained the shares of MRNS in report on Tuesday, March 8 with “Buy” rating. The company was maintained on Tuesday, June 14 by Jefferies. The firm has “Buy” rating given on Wednesday, August 10 by Jefferies. Below is a list of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) latest ratings and price target changes.

The stock increased 6.25% or $0.38 during the last trading session, reaching $6.46. About 1.09 million shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has declined 74.89% since February 15, 2017 and is downtrending. It has underperformed by 91.59% the S&P500.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $261.18 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.

More news for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) were recently published by:, which released: “EcoR1 Capital, LLC Buys Dicerna Pharmaceuticals Inc, Apellis Pharmaceuticals …” on February 15, 2018.‘s article titled: “Marinus Pharmaceuticals to Attend Upcoming Investor Conferences” and published on February 07, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.